Table 1 Demographics and baseline characteristics for patients treated in the trial
Baseline characteristic | MK-2206 dosing cohort | ||||
|---|---|---|---|---|---|
45 mg QOD | 60 mg QOD | 135 mg QW | 200 mg QW | All cohorts | |
(n = 3) | (n = 11) | (n = 11) | (n = 6) | (N = 31) | |
Gender, n (%) | |||||
 Male | 0 (0.0) | 1 (9.1) | 0 (0.0) | 2 (33.3) | 3 (9.7) |
 Female | 3 (100.0) | 10 (90.9) | 11 (100.0) | 4 (66.7) | 28 (90.3) |
Age (years) | |||||
 Median | 44 | 55.5 | 49 | 48.5 | 51.5 |
 Range | 36 to 52 | 44 to 67 | 37 to 61 | 38 to 59 | 36 to 67 |
Cancer type, n (%) | |||||
 Breast | 3 (100.0) | 10 (90.9) | 11 (84.6) | 3 (50.0) | 27 (87.1) |
 Gastric | 0 (0.0) | 1 (9.1) | 0 (0.0) | 3 (50.0) | 4 (12.9) |
Cancer stage, n (%) | |||||
 Intravenous | 3 (100.0) | 11 (100.0) | 11 (100.0) | 6 (100.0) | 31 (100.0) |
ECOG status, n (%) | |||||
 0 | 3 (75.0) | 7 (63.6) | 10 (91.0) | 4 (66.7) | 24 (77.4) |
 1 | 0 (0.0) | 4 (36.4) | 1 (9.0) | 2 (33.3) | 7 (22.6) |
Number of prior therapies, n (%) | |||||
 1 or 2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 2 (6.5) |
 ≥3 | 3 (100.0) | 11 (100.0) | 11 (100.0) | 4 (66.7) | 29 (93.5) |